Please login to the form below

Not currently logged in
Email:
Password:

Vyndaqel

This page shows the latest Vyndaqel news and features for those working in and with pharma, biotech and healthcare.

Pfizer CEO says COVID-19 vaccine efficacy data could come ‘soon’

Pfizer CEO says COVID-19 vaccine efficacy data could come ‘soon’

This increase was helped by a 125% increase in global revenues for its rare disease med Vyndaqel (tafamidis), totalling $351m.

Latest news

  • Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy

    EU approval will help drug achieve blockbuster status. Pfizer’s resurgent rare disease drug Vyndaqel has had its uses extended by the EMA, becoming the first drug in the EU for ... Prior to Vyndaqel, treatment options for patients with ATTR

  • Vyndaqel a bright spot as Pfizer comes under pressure Vyndaqel a bright spot as Pfizer comes under pressure

    The big boost for Pfizer came from  Vyndaqel/Vyndamax (tafamidis) for rare disease transthyretin-mediated amyloidosis (ATTR), which swelled to $213m in the fourth quarter from just $39m a year earlier ... As of the end of 2019 more than 9, 000 ATTR

  • Alnylam gains key NICE approval for Onpattro Alnylam gains key NICE approval for Onpattro

    decision. The two rivals also face competition from Pfizer’s Vyndaqel (tafadamis). It has been available in Europe for a number of years as a polyneuropathy treatment, but recently gained US ... The company also highlighted the fact that around a third

  • Pfizer buys dwarfism drug company Therachon for $810m Pfizer buys dwarfism drug company Therachon for $810m

    The deal adds to Pfizer’s rare disease portfolio, which just chalked up a major success with the approval of tafamidis products Vyndaqel and Vyndamax for transthyretin amyloid cardiomyopathy (ATTR-CM)

  • Speedy approval for Pfizer's Onpattro rival Speedy approval for Pfizer's Onpattro rival

    Both Vyndamax and Vyndaqel are expected to reduce cardiovascular mortality by 30% and cut cardiovascular related hospitalisation by 32%, strong claims which will help fuel their uptake. ... Vyndaqel has been priced at $225, 000 per year, half the price

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics